Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMK389 in chronic pulmonary sarcoidosis
2018-000381-11Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Pulmonary Sarcoidosis and pulmonary sarcoidosis comparing CMK389 with Placebo (2 arms). Primary endpoint: Change in forced vital capacity percent predicted. Started Jan 2020; status: completed.
02
Drugs
CMK-389
03
Conditions
Chronic Pulmonary Sarcoidosispulmonary sarcoidosis
Beyond the preview
Go deeper on 2018-000381-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000381-11.